T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis by Ruocco, Gabriella et al.
Clinical Science (2015) 129, 291–303 doi: 10.1042/CS20140608
T helper 9 cells induced by plasmacytoid dendritic
cells regulate interleukin-17 in multiple sclerosis
Gabriella Ruocco*, Silvia Rossi†, Caterina Motta†, Giulia Macchiarulo†, Francesca Barbieri†,
Marco De Bardi*, Giovanna Borsellino*, Annamaria Finardi‡, Maria Grazia Grasso§, Serena Ruggieri‖,
Claudio Gasperini‖, Roberto Furlan‡, Diego Centonze†¶, Luca Battistini* and Elisabetta Volpe*
*Neuroimmunology Unit, Santa Lucia Foundation, Rome 00143, Italy
†Dipartimento di Medicina dei Sistemi, University Tor Vergata, Rome 00133, Italy
‡Neuroimmunology Unit, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy
§Multiple Sclerosis Centre, Santa Lucia Foundation, Rome 00179, Italy
‖Department of Neuroscience “Lancisi”, San Camillo Hospital, Rome 00151, Italy
¶Neuroimmunology and Synaptic Plasticity Unit, Santa Lucia Foundation, Rome 00143, Italy
Abstract
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by persistent
inflammation orchestrated by cluster of differentiation (CD) 4 T helper (Th) cells. In particular, Th1 and Th17 cells
amplify, whereas T regulatory (Treg) cells moderate inflammation. The role of other Th subsets in MS is not clear. In
the present study, we investigated the generation of different Th responses by human dendritic cells (DCs) in MS.
We compared the production of several Th cytokines by naive CD4+ T-cells polarized with myeloid and plasmacytoid
DCs (mDCs and pDCs) in healthy donors (HD) and relapsing–remitting (RR)-MS patients. We found that
resiquimod-stimulated mDCs were able to activate Th17 differentiation, whereas pDCs induced interleukin
(IL)-10-producing Th cells. Surprisingly, resiquimod-stimulated pDCs from MS patients also significantly induced the
differentiation of Th9 cells, which produce IL-9 and are known to be involved in allergic diseases. We investigated
the potential role of IL-9 in MS. We found that IL-9 activated signal transducer and activator of transcription (STAT) 1
and STAT5 phosphorylation and interfered with IL-17 and interferon (IFN) regulatory transcription factor (IRF)-4
expression in Th17-polarized cells. Moreover, in the cerebrospinal fluid (CSF) of 107 RR-MS patients, IL-9 inversely
correlated with indexes of inflammatory activity, neurodegeneration and disability progression of MS. High levels of
IL-9 were associated with the absence of IL-17 in the CSF of RR-MS patients. Our results demonstrate a
Th9-inducing potential of pDCs in MS, suggesting an immunoregulatory role leading to attenuation of the
exaggerated Th17 inflammatory response.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of
the central nervous system (CNS). Autoreactive T-cells that are
normally controlled by ‘the tolerance machinery’ generate
autoimmune reactions against myelin, thus resulting in severe
inflammation and CNS damage [1]. Cytokine-producing cluster
of differentiation (CD) 4 T helper (Th) cells act as prin-
cipal modulators of the effector T-cell immune response. Upon
Abbreviations: ARR, annualized relapse rate; CD, cluster of differentiation; CNS, central nervous system; CSF, cerebrospinal fluid; DC, dendritic cell; EAE, experimental autoimmune
encephalomyelitis; EDSS, expanded disability status scale; HD, healthy donor(s); H-IL9, high IL-9; i.v., intravenously; IFN, interferon; IL, interleukin; IL-9R, IL-9 receptor; IRF, interferon
regulatory transcription factor; L-IL9, low IL-9; mDC, myeloid dendritic cell; MS, multiple sclerosis; MSSS, MS severity scale; MV, macular volume; NfL, neurofilament light chain; OCT,
optical coherence tomography; OR, odds ratio; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid dendritic cell; PI, progression index; RNFL, nerve fibre layer; ROR, retinoic
acid-related orphan receptor; RR, relapsing–remitting; RT, reverse transcription; SE, standard error; STAT, signal transducer and activator of transcription; TGF, transforming growth
factor; Th, T helper; TLR, Toll-like receptor; TNF, tumour necrosis factor; Treg, T regulatory.
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activation by the innate immune system, distinct Th lineages
are generated from naive CD4+ T-cells depending on the envir-
onmental signals present during activation [2]. Until now, two
major cell subsets, Th1 and Th2, were described in the adaptive
immune responses established to eradicate pathogens through
the production of interferon (IFN)-γ or interleukin (IL)-4, -5 and
-13 respectively [3,4]. In the past 10 years, three additional Th
cell subtypes have been discovered and designated Th17, Th9
and Th22 cells, according to the signature cytokine secreted by
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each subset after activation (IL-17, IL-9 and IL-22 respectively)
[5–7]. Moreover, dendritic cells (DCs) may also lead to the devel-
opment of T regulatory (Treg) cells, which exert inhibition and
neutralization of effector cells by several mechanisms, includ-
ing release of IL-10 [8,9]. Treg cells are known to be protective
in MS [10], whereas effector Th1 and Th17 cells contribute to
tissue inflammation and exacerbation of autoimmune pathology
[11,12]. Moreover, the presence of IFN-γ -producing Th1 and
IL-17-producing Th17 cells in the cerebrospinal fluid (CSF) of
MS patients firmly points to their involvement in human CNS
inflammation [13,14].
The presence of Th22 cells in MS has also been previously
described [15,16], whereas the differentiation and the role of Th9
cells in the disease have never been investigated.
The differentiation of Th subsets is mediated by activated
DCs. There are two main subsets of peripheral blood DCs in
humans: myeloid (mDC) and plasmacytoid (pDC), each express-
ing distinct sets of pattern-recognition receptors and responding
to different microbial products, suggesting that they may activ-
ate different Th cell responses [17,18]. Thus, the response of
DCs to activating signals and the activation of an appropriate
Th response is a critical issue in autoimmune disorders, where
the balance between inflammatory and regulatory responses is
deregulated.
To date, little is known about the generation of Th cells in MS
patients. In the present study, we identified a pDC-driven Th9
immunoregulatory pathway, which may contribute to decrease
pathogenic Th17 inflammation and disease progression.
MATERIALS AND METHODS
MS subjects for blood and CSF collection
Patients with relapsing–remitting (RR)-MS according to estab-
lished criteria [19] were enrolled in the study. Demographic and
clinical data of RR-MS patients included in the study are de-
scribed in Table 1 (for blood sampling) and Table 2 (for CSF
sampling).
As controls, we used blood or CSF from age- and gender-
matched individuals without inflammatory or degenerative dis-
eases of the central or peripheral nervous system. These subjects
were volunteers that underwent drawing (for blood) or patients
who underwent lumbar puncture because of a clinical suspicion of
acute peripheral neuropathy, meningitis or subarachnoidal haem-
orrhage, which were not confirmed (for CSF).
Approval by the ethics committee of the Policlinico Tor Ver-
gata, Santa Lucia Foundation and San Camillo Hospital and writ-
ten informed consent in accordance with the Declaration of Hel-
sinki from all participants were obtained before study initiation.
After their admittance, patients underwent blood and CSF
sampling, full neurological assessment and brain (and in selec-
ted case also spinal) MRI scan. All patients included in the blood
study did not take immunomodulant or immunosuppressive com-
pounds at least 2months before recruitment (Table 1).All subjects
included in the CSF study were not treated before CSF collection
(Table 2).
Table 1 Demographic and clinical
characteristics of MS subjects at the time of
naive-DC co-culture
Parameter Value
Number 26
Gender (male/female) 6/20
Age (years) 42 +− 14
Disease duration (years) 13 +− 12
EDSS 2 +− 2.0
MRI (gadolinium+/−) 5/21
For the follow-up of the CSF study, all RR-MS patients star-
ted immunomodulatory treatment (IFN-β1a, n= 44; IFN-β1b,
n= 33; glatiramer acetate, n= 30) after CSF collection. Mitox-
antrone [12 mg/m2 i.v. (intravenously) every 3months with a life-
time maximum of 140 mg/m2], natalizumab (300 mg i.v. every 4
weeks) and fingolimod [0.5 mg p.o. (per os) every day] were con-
sidered as second-line treatments for patients who experienced at
least two relapses during 1 year of therapy with other approved
immunomodulatory agents. Demographic and clinical informa-
tions were derived from medical records. MS disease onset was
defined as the first episode of focal neurological dysfunction in-
dicative of MS. Disease duration was estimated as the number
of years from onset to the last assessment of disability. Relapses
were defined as the development of new or recurrent neurolo-
gical symptoms not associated with fever or infection lasting for
at least 24 h.
Purification of naive CD4+ T lymphocytes from
adult blood
Peripheral blood mononuclear cells (PBMCs) were isol-
ated by Ficoll gradient centrifugation (GE Healthcare)
from 100 ml of whole blood of RR-MS patients or healthy
donor (HD) volunteers, stained with the following antibod-
ies: lineage (CD3, CD14, CD16, CD19)–PE/eCy7 (phyco-
erythrin/indotricarbocyanine) (Coulter), CD11c–FITC (Miltenyi
Biotech), human leukocyte antigen (HLA)–DR–V450 (eBios-
cience), CD4–ECD (Coulter), CD27–APC (allophyco-
cyanin) (eBioscience), CD45RA–phycoerythrin (PE) (BD). pDC
(lineage−, CD4+, CD11c−), mDC (Lineage−, CD4+, CD11c+),
CD4+ naive T-cells (lineage+, CD4high, CD45RAhigh, CD27+)
were sorted simultaneously with a MoFlo high speed cell sorter
(Coulter). Gating strategy is shown in Supplementary Figure
S1(A). All sorted cells had a purity of over 96%, as shown by
flow cytometry (Supplementary Figure S1B).
Cells purified from healthy blood donor volunteers were used
as controls in the experiment of Figure 1; cells purified from buffy
coats (Policlinico Tor Vergata) were used in all other experiments
where comparison with fresh blood from MS patients was not
required.
Th cell differentiation assay
Naive CD4+ T-cells were cultured in 96-well round-bottomed
plates (Corning) at a density of 5× 104 per well in X-VIVO 15
serum-free medium (Lonza) in the presence of Dynabeads CD3–
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Table 2 Demographic and clinical characteristics of MS subjects at the time of CSF collection
IL-9
Total High (>100 pg/ml) Low (<100 pg/ml) P
Number 107 50 57 –
Gender (male/female) 42/65 19/31 23/34 0.84
Age (years) 32.0 +− 6.0 32.2 +− 6.1 31.8 +− 6.0 0.77
Disease duration (years) 4.8 +− 2.8 5.3 +− 2.9 4.4 +− 2.8 0.11
EDSS 1.6 +− 1.0 1.3 +− 0.9 2.0 +− 1.0 <0.05
MRI (gadolinium+/−) 44/63 21/29 23/34 1.0
CD28 T-cell expander (one bead per cell; Life Technologies) and
indicated cytokines: IL-1β (10 ng/ml), IL-6 (20 ng/ml), trans-
forming growth factor (TGF)-β (1 ng/ml) and IL-23 (100 ng/ml)
(Miltenyi) for Th17 differentiation, as previously described [20],
TGF-β (5 ng/ml) and IL-4 (50 ng/ml; Miltenyi) for Th9 differen-
tiation. In some experiments recombinant human IL-9 and IL-2
(Miltenyi) were used. After 5–6 days, cells were harvested, ex-
tensively washed and viability was determined by Trypan Blue
exclusion. Then, 1× 106 cells/ml were re-stimulated with Dyna-
beads CD3–CD28 T-cell expander (one bead per cell) for 24h
[for cytokine analysis and reverse transcription (RT)-PCR].
Analysis of cytokine production
Cytokines in culture supernatantsweremeasured by IL-17ELISA
(R&DSystems), IL-9 ELISA (eBioscience), IFN-γ , IL-13, IL-22
and IL-10 Flow Cytomix (eBioscience) according to the manu-
facturer’s instructions.
Real-time quantitative RT–PCR
Total RNA was extracted using an RNeasy Microkit (Qiagen).
A mixture containing random hexamers, Oligo (dT)15 (Promega)
and Super Script II Reverse Transcriptase (Life Technologies)
were used for cDNA synthesis. Transcripts were quantified by
real-time quantitative PCR on an LC480 (Roche) with Applied
Biosystems predesigned TaqMan Gene Expression Assays and
Taqman Gene expression Master Mix (Life Technologies). The
following probeswere used (identified byAppliedBiosystems as-
say identification number): IL-17A, retinoic acid-related orphan
receptor (ROR) C, IFN regulatory transcription factor (IRF)-4,
IL-9 receptor (IL-9R). For each sample, mRNA abundance was
normalized to the amounts of ribosomal protein L-34.
Western blot analysis
For protein extraction, Th cells were resuspended in RIPA buf-
fer (50 mM Tris/HCl, pH 8, 200 mM NaCl, 2 mM EDTA, 1%
NP-40, 0,5% sodium deoxycholate, 0.05% SDS, 1 mMNa3VO4,
1 μg/ml leupetin, 1 μg/ml aprotinin, 5 mMNaF and 1 mMPMSF
freshly added). After 15 min on ice, cell lysates were centrifuged
for 15 min at 15 000 g at 4 ◦C and the supernatants were col-
lected and used for Western blot analyses. Cell extracts were
diluted in Laemmli buffer and boiled for 5 min at 95 ◦C. Pro-
teins were separated on SDS/PAGE (8% gel) gels and transferred
on to nitrocellulose membranes (Whatman, Sigma–Aldrich, GE
Healthcare Life Science) using a wet blotting apparatus (Amer-
sham Biosciences). Membranes were saturated for 1 h at room
temperature with 3% non-fat dry milk in PBS, containing 0.1%
Tween 20. Membranes were incubated with the following an-
tibodies overnight at 4 ◦C: rabbit polyclonal anti-human phos-
pho signal transducer and activator of transcription (STAT) 1
(Cell Signaling Technology; 1:1000 dilution), rabbit polyclonal
anti-human phospho-STAT3 (Cell Signaling Technology; 1:1000
dilution), mouse IgG1 anti-human phospho-STAT5 (BD Trans-
duction Laboratories; 1:500 dilution), mouse anti-human actin
(Abcam; 1:10000 dilution). All antibodies were diluted in 3%
non-fat dry milk in PBS, containing 0.1% Tween 20. Secondary
anti-mouse or anti-rabbit IgGs conjugated to horseradish per-
oxidase (Cell Signaling Technology) were incubated with the
membranes for 1 h at room temperature at a 1:2000 dilution in
PBS containing 0.1% Tween 20. Immunostained bands were de-
tected using a chemiluminescence method (Pierce ECL Western
Blotting Substrate, Thermo Scientific).
CSF analysis
CSF was centrifuged to eliminate cells and cellular debris and
immediately stored at −80 ◦C until analysed. All samples were
processed using identical standardized procedures usingBio-Plex
Multiplex Cytokine Assay (Bio-Rad Laboratories), according to
the manufacturer’s instructions. Concentrations of IL-4, IL-9 and
IL-17 were calculated according to a standard curve generated
for each target and expressed as pg/ml. When the concentrations
of the cytokines were below the detection threshold, they were
assumed to be 0 pg/ml.
Neurofilament light chain (NfL) levels in CSF were assayed
using a commercially available ELISA kit (UmanDiagnostics
NF-light assay). The levels of NfL in CSF were determined by
fitting data to a four-parameter standard curve using theGraphPad
Prism Software Package.
Analysis of clinical parameters
The annualized relapse rate (ARR) was defined as the number
of relapses per year. Disability was determined by a specially
trained and certified examining neurologist using the expanded
disability status scale (EDSS), a 10-point disease severity score
derived from nine ratings for individual neurological domains
[21]. The EDSS, evaluated every 6 months since diagnosis, was
used in combination with disease duration to calculate two meas-
ures of disease severity, the progression index (PI) and the mean
MS severity scale (MSSS). PI was defined as EDSS/disease dur-
ation [22]. The MSSS is an algorithm that relates EDSS scores
to distribution of disability in patients with comparable disease
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durations [23]. Four years of follow-up were available for each
patient.
Optical coherence tomography
Medical history with respect to visual symptoms was taken from
all MS subjects. Self-report and physician report were confirmed
by record review. A subset of RR-MS patients (n= 88) without
history of optic neuritis and ophthalmological disease underwent
measurement of nerve fibre layer (RNFL) thickness and macu-
lar volume (MV) for both eyes using Stratus Optical Coherence
Tomography (OCT) software version 4.0.2, Carl Zeiss Meditec,
Inc. [22,24]. Briefly, forMV, retinal thicknesswasmeasured auto-
matically as the distance between the vitreoretinal interface and
the anterior boundary of the retinal pigment epithelium. Stratus
OCT images were generated using the fast map scan protocol
consisting of six radial scans spaced 30◦ apart, with each scan
measuring 6 mm in length. Each image had a resolution of 10 μm
axially and 20 μm transversally. All Stratus OCT images had sig-
nal strength of 6 μm. RNFL thickness measurements were read
from the automated measurements generated by the machine
using the Fast RNFL analysis. For the study, scanning was per-
formed after pharmacological dilation. Average RNFL thickness
for 360◦ around the optic disc was recorded. Values were ad-
justed for age. One randomly chosen eye from each subject was
included in the study. Testing was performed by trained techni-
cians experienced in examination of patients for research studies
and patients wore their habitual glasses or contact lenses for dis-
tance correction.
MRI
MRI examination (1.5 Tesla) consisted of dual-echo proton dens-
ity, fast fluid-attenuated inversion recovery, T2-weighted spin-
echo images and pre-contrast and post-contrast T1-weighted
spin-echo images. All images were acquired in the axial ori-
entation with 3-mm-thick contiguous slices. The presence of
gadolinium (0.2 ml/kg i.v.)-enhancing lesions was evaluated by
a neuroradiologist who was unaware of the patient’s clinical
details [25].
Statistical analysis
For pair-wise comparisons of different conditions from the same
donors or different donors, we used a non-parametric two-tailed
paired or unpaired Student’s t test respectively.P-values of 0.05 or
less were considered statistically significant. Differences among
groupswere compared by univariate analysis using Student’s t test
orMann–Whitney test for continuous variables and Fisher’s exact
test for categorical variables. Survival curves were analysed using
log-rank (Mantel–Cox) test. Correlation analysis was performed
by calculating Pearson’s coefficient. Logistic regression model
was constructed for the disability as outcome. We estimated the
degree of disability by means of the dichotomous EDSS (cut-
off point of 4.0, at which restriction in ambulation starts to be
appreciated).
As reported in the literature, the lower scale values (0–4.0)
are influenced by impairments detected by the neurological exam
of eight functional systems, whereas the values above 4.0 are
mainly based on walking ability and values above 6.0 mainly on
patients’ handicaps [21,26–28]. Acquisition of EDSS steps 4 or
above is considered a sufficient milestone because, once reached,
MS inevitably progresses [29]. In line with this, the degree of
disability in MS is usually analysed by means of the dichotomous
EDSS with a cut-off point of 4.0 [30–32].
Six variables (years of disease, age, gender, ARR, use of
second-line treatments and CSF cytokine contents) were included
as predictor variables. Coefficients with standard error (SE) and
odds ratio (OR) with 95% confidence interval are provided. Two-
way ANOVAs were performed to analyse the main effects and
interactions of two conditions on the dependent variables.
Data are presented as means +− S.D. A P-value of less than
0.05 was considered statistically significant.
RESULTS
Plasmacytoid dendritic cells from RR-MS patients
induce Th9 polarization
Given the crucial role of DCs in polarizing Th responses, we
hypothesized a differential role ofDCs obtained fromMSpatients
comparedwithDCs fromHD in driving Th differentiation. To test
this hypothesis, naiveCD4+ T-cells fromHDandRR-MSpatients
were co-cultured with autologous pDCs or mDCs stimulated with
resiquimod (R-848), an agonist for Toll-like receptor (TLR) 7
expressed by pDCs and for TLR8 expressed by mDCs (Table 1).
We analysed cytokine production by polarized Th cells after
6 days of co-culture. We found that IFN-γ and IL-13 were not in-
duced after Th cell activation by either pDCs ormDCs in bothHD
and MS (Figures 1A and 1B). In contrast, in the same conditions,
stimulated mDCs induced significant levels of IL-17 whereas
pDC induced IL-10 by Th cells in both groups of individuals
(Figures 1C and 1D).
We found that resiquimod-simulated pDCs also promoted
Th22 differentiation in HD (Figure 1E) and surprisingly, activ-
ated pDCs fromMS patients induced significant IL-9 production
by Th cells (Figure 1F). The induction of IL-9 by pDCs fromMS
patients was found regardless of the phase of disease, indicating
that blood pDCs are not influenced by the stage of inflammation
(results not shown). We verified that pDCs fromMS patients and
HD expressed similar levels of TLR 7, indicating that differences
in Th9 induction were not related to a different sensitivity to the
stimulus (Supplementary Figure S2).
In order to investigate whether the higher Th9 polarization
observed in MS patients compared with HD was related to a dif-
ferential response of pDCs or rather to a specific predisposition
of naive CD4+ T-cells in MS patients, we cultured naive CD4+ T-
cells with Th9-polarizing cytokines in the presence of anti-CD3
and anti-CD28. IL-9 production in Th9 conditions was com-
pared with control Th0, generated in the absence of polarizing
cytokines. The results showed that naive CD4+ T-cells cultured
in the presence of IL-4 and TGF-β produced similar levels of IL-
9 in HD and in MS patients (Supplementary Figure S3). These
results indicated that the Th9 differentiation machinery in naive
CD4+ T-cells was not altered in MS patients, implying that the
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Figure 1 pDCs from RR-MS patients induce Th9 polarization
pDCs and mDCs from HD and RR- MS patients were activated for 24 h with resiquimod and co-cultured with autologous
naive CD4+ T-cells (ratio 1:1) in the presence of anti-CD3-CD28-coated beads for 6 days, then re-stimulated for 24 h.
Protein expression of T-cell-derived cytokines IFN-γ (A), IL-13 (B), IL-17 (C), IL-10 (D), IL-22 (E) and IL-9 (F) was analysed
by Flow Cytomix or by ELISA. A paired Student’s t test was used to compare no cytokines and Th9 cocktail. An unpaired
Student’s t test was used to compare HD and RR-MS. *P< 0.05, **P< 0.005.
differential Th9 polarization observed in MS was rather related
to a peculiarity of pDCs.
IL-9 in the CSF of RR-MS subjects inversely
correlates with disease severity
To investigate the role of IL-9 in MS, IL-9 levels were meas-
ured in the CSF of control subjects (n= 70, 27 males, aged
31.6+− 6.1 years) and RR-MS patients (n= 107, 42 males,
aged 32.0+− 6.0 years). No significant difference was observed
between these two groups (control: 132.3+− 230.3 pg/ml; MS:
193.3+− 244.6 pg/ml; P = 0.09). Furthermore, no significant dif-
ferences were found categorizing MS patients according to the
absence (gadolinium–, n= 63; 180.6+− 231.4 pg/ml) or the pres-
ence (gadolinium+, n= 44; 211.4+− 264.1 pg/ml) of contrast-
enhancing lesions at baseline MRI (P> 0.1), indicating that IL-9
levels in the CNS were not influenced by the acute stage of
inflammation.
To further investigate the potential role of IL-9 on disease
course, RR-MS patients were stratified according to IL-9 levels
in the CSF in a high IL-9 (H-IL9, n= 50) and a low IL-9 group
(L-IL9, n= 57), using a cut-off value of 100 pg/ml (Table 2),
which was near to mean levels in controls and followed sample
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Figure 2 IL-9 in the CSF of RR-MS subjects inversely correlates with disease severity
Survival analysis for the time to first clinical relapse since diagnosis, among subjects with high or low levels of IL-9 in
the CSF (100 pg/ml as cut-off value; A). Mean ARR (B), the number of subjects treated with second-line drugs (C)
and the disability progression, measured as a PI (D) or MSSS (E), were reported in RR-MS subjects with L-IL9 and H-IL9 in
the CSF (100 pg/ml as cut-off value). NfL, a soluble marker of neurodegeneration, was measured by ELISA (F) in CSF of
RR-MS subjects with L-IL9 and H-IL9 (100 pg/ml as cut-off value). Interaction between IL-9 in CSF and disease duration
was analysed based on OCT parameters, RNFL thickness (G) and MV (H). Data are represented as means +− S.D. of 50
H-IL9 and 57 L-IL9 MS patients. *P< 0.05.
distribution for statistical analysis. Moreover, we fixed the cut-off
level at 100 pg/ml to divide the 107 MS patients in two balanced
groups, in order to have a similar number of patients in the H-
and L-IL9 groups.
We found that the time to first clinical relapse was affected
by the CSF levels of IL-9, being lower in the L-IL9 group,
as assessed by survival curve analysis (16.9+− 11.8 compared
with 24.1+− 14.2 months; P= 0.007; Figure 2A). Consistently,
the mean ARR in the first 4 years since diagnosis and the num-
ber of subjects treated with second-line drugs were significantly
lower among subjects with high CSF levels of IL-9 (H-IL9:
28% compared with L-IL9: 51%; P< 0.05 for each comparison;
Figures 2B and 2C). These data show that high level of IL-9 in
the CNS is associated with a less severe inflammatory disease
activity in RR-MS.
Furthermore, baseline EDSS, PI and MSSS were signific-
antly lower in the H-IL9 group (P< 0.05 for each comparison;
Figures 2D and 2E), suggesting that increased levels of IL-9
within the CNS could contrast disability progression in RR-MS
patients. Multivariate analysis confirmed the protective effect of
IL-9 on disability progression besides its anti-inflammatory activ-
ity, predicting a lower risk to reach EDSS 4.0 in the H-IL9 group
(coefficient: −1.43, SE: 0.65, OR: 0.24, P= 0.02), at equal val-
ues of age, gender, disease duration, ARR and use of second-line
treatments.
We then analysed the CSF contents for NfL, which is known
to be a valid biomarker of axonal damage and neurodegenera-
tion [33]. Our results showed lower levels of NfL in the H-IL9
group (P< 0.05; Figure 2F), suggesting a neuroprotective role
for IL-9 in MS. The axonal and neuronal cell loss in MS has been
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convincingly associated with reduced RNFL thickness andMV at
the OCT [34–36]. Thus, we investigated the possible relationship
between IL-9–CSF contents and OCT parameters in a subgroup
of RR-MS patients with similar disease duration (disease dur-
ation 4 years: H-IL9 n= 15, L-IL9 n= 24; disease duration
>4 years: H-IL9 n= 25, L-IL9 n= 24). A significant effect of
IL-9 CSF levels was revealed analysing both RNFL thickness
(F = 50.2, P< 0.0001) and MV (F = 63.7, P< 0.0001), in-
dicating a more severe damage of neuronal structures within the
L-IL9 group. Disease duration slightly affected OCT parameters
(RNFL thickness: F = 10.7, P< 0.01; MV: F = 11.4, P< 0.01)
with a significant interaction with IL-9 contents (RNFL thick-
ness: F = 4.8, P< 0.05; MV: F = 7.1, P< 0.01), confirming less
severe neurodegenerative damage in subjects with H-IL9 levels
in the CSF, a longer disease duration notwithstanding (Figures 2G
and 2H).
Since IL-9 is a cytokine associatedwith Th2 cells, we assessed
the specificity of Th9 in the protective effects on MS, replicat-
ing the analyses with CSF levels of IL-4, the major cytokine
involved in Th2 responses. No association was found between
CSF IL-4 levels and any index of disease severity. Comparing
between a set of homogeneous patients (no differences in terms
of demographic characteristics) with undetectable (n= 66) and
detectable (n= 41) CSF levels of IL-4, we found that mean ARR
and PI were not significantly different in the 4 years of follow-up
(P> 0.05 for each parameter; Supplementary Figures S4A and
S4B). In line with this observation, no significant differences
in NfL contents were found between the two groups of patients
(P> 0.05), ruling out the involvement of IL-4 in neuroprotective
effects (Figure 3C). Of note, a lack of correlation was also found
between IL-9 and IL-4 CSF levels (P= 0.72, r = 0.03), confirm-
ing an independent value of the two cytokines (Supplementary
Figure S4D).
IL-9 activates STAT1, STAT5 and reduces IL-17 and
IRF4 expression in Th17 cells
Previous data demonstrated an immunosuppressive function of
IL-9 that indirectly inhibited the production of pro-inflammatory
cytokines [37]. In order to investigate the role of IL-9 in modulat-
ing T-cell responses, we analysed the effect of IL-9 on different
Th subsets expressing the IL-9R (Supplementary Figure S5). We
found that, among all Th profiles, Th17 cells were the most re-
sponsive to IL-9 regarding the ability to produce cytokines. IL-9
reduced IL-17 production by Th17 cells and its inhibitory ef-
fect was dose-dependent (Figure 3A). Moreover, we found that
IL-9 was able to down-regulate IL17 mRNA, indicating that it
exerts its inhibitory effect on IL-17 at the transcriptional level
(Figure 3B). IL-9 had no effect on other cytokines produced by
Th17 cells, such as TNF-α, IL-6, IFN-γ and IL-10 (Supplement-
ary Figure S6).
In order to identify the mechanisms affected by IL-9 during
Th17 polarization, we analysed the key transcription factor for
the differentiation programme of Th17 cells, RORγ t, encoded
by the RORC gene [38]. We found a strong expression of RORC
transcript in Th17 cells, but its expression was not modulated by
IL-9 treatment (Figure 3C).
However, RORγ t is not the unique transcription factor regu-
lating IL-17 expression. IRF4 was reported to be also essential
for Th17 cell differentiation [39]. In this context, we confirmed
the induction of IRF4 in Th17 cells and we found that IL-9 sig-
nificantly reduced IRF4 transcript (Figure 3D), suggesting that
IL-9 reduced the optimal expression of IL-17 by Th17 cells by
inhibiting IRF4 expression.
It is known that upon binding to its cell-surface receptor IL-9
induces recruitment and cross-phosphorylation of Janus kinases
(JAKs) 1 and 3 followed by activation of STAT1, STAT3 and
STAT5. Consequently, STAT complexes translocate to the nuc-
leus to drive transcription of IL-9-inducible genes [40]. Thus,
we analysed the phosphorylation of STAT1, STAT3 and STAT5
on Th17 cells stimulated with IL-9. Interestingly, STAT3, known
to be involved in Th17 polarization [41,42] was already phos-
phorylated on Th17 cells and no modulation was measured after
stimulation with IL-9. In contrast, STAT1 and STAT5, which are
known to inhibit Th17 polarization [43,44], were activated by
IL-9 (Figure 3E) suggesting their potential role in IL-9-mediated
modulation of the Th17 response.
IL-9–IL-17 interaction is associated to disability
progression and neurodegeneration in MS
Given the inhibitory effect of IL-9 on IL-17 production, we in-
vestigated whether IL-9 could reduce IL-17 levels also in vivo.
We analysed the CSF contents of the two cytokines in RR-MS
patients. The proportion of subjects with undetectable levels of
IL-17 was significantly higher in the H-IL9 group (90% com-
pared with 58%, P< 0.01; Figure 4A).
A 2× 2 ANOVA constructed with IL-9 and IL-17, as explor-
atory conditions, revealed a significant interaction between the
two cytokines on both PI (F = 4.2, P< 0.05; Figure 4B) and NfL
CSF contents (F = 4.3, P< 0.05; Figure 4C). In fact, among
subjects of the L-IL9 group, the concomitant detection of IL-17
significantly increased indexes of disability progression (PI) and
neurodegeneration (NfL levels).
Conversely, the presence of IL-17 in the CSF was not associ-
ated with increases in the ARR (F = 1.1, P> 0.05), without a
significant interaction with IL-9 (F = 0.35, P> 0.05), ruling out
the involvement of IL-17 in the effects of IL-9 on inflammatory
activity. A significant effect on relapse rate was in fact observed
only for IL-9 levels (F = 4.3, P< 0.05; Figure 4D), in line with
primary univariate analysis.
Thus, the inverse correlation of IL-17 and IL-9 observed in
the CSF of MS patients indicated that inhibition of IL-17 by IL-9
might occur also in vivo.
DISCUSSION
This is the first study comparing the polarizing ability of pDCs
and mDCs derived from the same MS patient in response to the
same TLR agonist in an autologous setting.We found that the two
DC subsets activate different Th responses: resiquimod-treated
pDCs induce IL-10, whereas resiquimod-treated mDCs drive IL-
17 production. In MS, bacterial or viral infection can trigger the
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Figure 3 IL-9 activates STAT1 and STAT5 and reduces IL-17 and IRF-4 expression by Th17 cells
Naive CD4+ T-cells were stimulated with anti-CD3 and anti-CD28 in the presence of Th17-polarizing cytokines for 5 days.
At day 4, cells were washed and cultured in fresh medium. After 12 h, cells were treated or not with IL-9 for the last period
of culture. IL-17 protein in the supernatants after 24 h of re-stimulation with anti-CD3–CD28 was analysed by ELISA. Data
are represented as means +− S.D. for seven donors (A); IL17 (B), RORC (C) and IRF4 (D) mRNA were analysed after
24 h of re-stimulation with anti-CD3–CD28 by RT–PCR; a paired Student’s t test was used to compare sample conditions.
*P< 0.05, **P< 0.005. STAT1, STAT3 and STAT5 were analysed by Western blot (E) and results from a representative
experiment are reported.
onset and/or relapses of the disease via mechanisms of molecu-
lar mimicry and via TLR signalling [10,45]. Our results sug-
gest that the same trigger (TLR7/8 agonist) activates both pDCs
and mDCs with consequent induction of opposite Th responses,
Treg and Th17 respectively, which mediate the balance between
regulation and inflammation. Thus, the type of DCwhich encoun-
ters the stimulus is crucial for the generation of the appropriate
Th response.
Our results are consistent with previous data showing that
incubation of human PBMC with TLR7/8 ligands promotes the
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Figure 4 IL-9–IL-17 interaction is associated with disability progression and neurodegeneration in MS
The number of RR-MS subjects with detectable (det) or undetectable (und) IL-17 in CSF of patients with L-IL9 and H-IL9 in
the CSF (100 pg/ml as cut-off value) was reported (A). Interaction between IL-9 and IL-17 CSF contents was performed
by analysing PI (B), NfL levels (C) and ARR (D) in RR-MS subjects with different levels of cytokines in CSF. Data are
represented as means +− S.D. of 50 H-IL9 and 57 L-IL9 MS patients. *P< 0.05.
differentiation of Th17 cells fromnaive T-cells [46]. In the present
study, we find that mDCs are responsible for Th17 induction. Di-
vergent results are shown in another report, where human pDCs
stimulated with TLR7 ligands promote Th17 differentiation from
naive T-cells [47]. However, in those experiments allogeneic co-
cultures were set up, in contrast with the autologous assays used
in our study and this could explain the discrepancy. Nonethe-
less, in line with that paper we observed that stimulated pDCs
enhance Th17 responses in memory CD4+ T-cells derived from
HD (results not shown).
The differentiation of human Th17 cells has been studied
using polyclonal activators and recombinant cytokines [20,48],
activatedmonocytes [49,50], inflammatoryDCs from ascites [51]
and mDCs stimulated with resiquimod [52]. In line with others,
we find that blood mDCs activated with resiquimod are capable
of polarizing autologous naive CD4+ T-cells in Th17 cells, in-
dicating that blood DCs are potential inducers of Th17 cells and
that an appropriate environment may disclose their potentiality.
We show that resiquimod-stimulated pDCs are capable of in-
ducing IL-10 producing cells. The induction of IL-10-producing
Treg cells by pDCs has been demonstrated following activation
with IL-3, CD40 ligand and TLR9 agonists [9,17,53]. This in-
dicates that activation of IL-10 is a typical feature of pDCs,
regardless of the nature of the activating stimulus.
We find that resiquimod-stimulated pDCs also promote Th22
differentiation in HD (Figure 1E) in accordance with previous
data demonstrating that oligodeoxynucleotides (CpG)-stimulated
pDCs efficiently prime for Th22 polarization through the release
of IL-6 and TNF-α [54]. Moreover, we observed for the first time
that pDCs from MS patients induce the Th9 profile.
Given the well-described plasticity of pDCs [18], the mod-
ulation of new Th profiles by activated pDCs could be expec-
ted. Recently, it was described that mDC stimulated with thymic
stromal lymphopoietin induce Th9 polarization in asthmatic pa-
tients [55]. However, the role of pDC in inducing the Th9 profile
has never been reported.
Although the presence of pDCs in different autoimmune
diseases, including systemic lupus erithematosus, psoriasis,
Sjogren’s syndrome, rheumatoid arthritis and MS has been ob-
served [56–59], their protective or inflammatory role is not clear.
On the other hand, IL-9 is a cytokine implicated in human and
murine asthma, anaphylaxis, resistance to nematode infection,
antiviral immunity and tumorigenesis [60–69]. The role of IL-9 in
autoimmunity has been investigated in the mouse model of MS,
experimental autoimmune encephalomyelitis (EAE). However,
these studies have generated contrasting results, which do not
allow assigning a clear role for IL-9 in this model [37,70,71].
The role of IL-9 in human autoimmunity has been investig-
ated in psoriasis, where it was shown that IL-9R is increased
in lesional compared with healthy skin [72] and in lupus eryth-
aematous, where IL-9 was reported to be highly expressed in
the serum [73,74]. However, the lack of correlations with clinical
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parameters does not permit to unequivocally define a specific role
of IL-9 in human autoimmunity, yet.
Our analysis correlates IL-9 levels in the CSF of RR-MS pa-
tients with the course of the disease. A previous study in MS
patients showed that IL-9 levels in the CSF were lower during
clinical relapses and increased following prednisolone treatment,
thus confirming the role of IL-9 in the maintenance of the remis-
sion phase in MS [75].
Consistent with our data, it has been demonstrated that mice
lacking IL-9R exhibit an increase in Th17 cells during EAE, sug-
gesting that IL-9 could have an inhibitory effect on Th17 cell
differentiation in vivo [37]. However, in the same paper, in vitro
experiments indirectly suggest that IL-9 enhances Th17 polariza-
tion [37]. Similarly, culture of human PBMC or of purified CD4+
T-cells with IL-9 determines an increase in IL-17 production [72].
The divergent effects of IL-9 on human cells could be due
to a differential outcome of IL-9 when it interacts with mixed
cellular populations present in whole PBMCs or in bulk CD4+
lymphocytes, compared with the highly purified CD4+ naive T-
cells used in the present study.
The activation of STAT1 and STAT5 by IL-9 on Th17 cells
indicates that the IL-9R on human Th17 cells is fully functional
and suggests that the inhibitory effect of IL-9 on IL-17 produc-
tion could be mediated by STAT1 or STAT5, which are already
known to inhibit Th17 polarization [43,44]. Consistent with our
data, the inhibition of IL-17 mediated by STAT5 is independent
of RORγ t. In fact, STAT5 directly represses IL-17 induction by
binding to the IL17 locus, where it removes accessible histone
marks and displaces STAT3 occupancy [44]. Our data identify a
new possible mechanism contributing to STAT5-mediated IL-17
inhibition, which involves repression of the transcription factor
IRF-4.
Importantly, the interaction between IL-17 and IL-9 reveals a
general mechanism regulating the Th17 response. In MS, activ-
ation of Th9 cells could be an important mechanism regulating
the pathogenic inflammation generated by Th17 cells. Moreover,
the production of IL-9 by Th17 cells [37] suggests an autocrine
loop in which IL-9 produced by Th17 cells participates in con-
trolling and reducing further amplification of the pathogenic and
inflammatory activity of these cells.
Our results reveal that in MS pDCs are the first trigger for the
activation of the immunoregulatory response of Th9 cells. Inter-
estingly, we found that IL-9 inversely correlates with the progres-
sion of MS, probably due to an in vivo inhibition of IL-17. Thus,
in the context of the discordant literature in the field, our findings
highlight an anti-inflammatory role for IL-9 in MS. The present
study adds another level of complexity to the intricate network
of cells and cytokines involved in MS and opens perspectives
on the possible involvement of Th9 cells in other autoimmune
diseases and in the progressive form of MS. Th9 cells could
have regulatory properties, ultimately contributing to protection
from inflammation (such as production of anti-inflammatory cy-
tokines) that go beyond their impact on Th17 cells.
Further studies aimed at characterizing human Th9 cells and
at identifying the mechanisms responsible for their activation by
pDCs could help discover new therapeutic targets to potentiate
an immunoregulatory response in MS.
CLINICAL PERSPECTIVES
 We have identified a novel regulatory role for IL-9 in MS.
 Our results reveal that pDCs are the first trigger which in-
duce IL-9 production and that this cytokine exerts anti-
inflammatory properties. Specifically, we show that IL-9 activ-
ates STAT1 and STAT5, interferes with IRF4 transcription and
reduces the production of the inflammatory cytokine IL-17.
Moreover, IL-9 expressed in the CSF of MS patients inversely
correlates with the severity of the disease and with the expres-
sion of IL-17 in the CSF.
 Thus, the mechanisms triggering IL-9 secretion and the ability
of this cytokine to reduce IL-17 production could be thera-
peutically targeted and amplified to reduce the inflammatory
response in MS.
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